Adbry and Eye infection - a phase IV clinical study of FDA data

Summary:

Eye infection is reported as a side effect among people who take Adbry (tralokinumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dupixent, and have Dermatitis atopic.

The phase IV clinical study analyzes which people have Eye infection when taking Adbry. It is created by eHealthMe based on reports of 1,898 people who have side effects when taking Adbry from the FDA, and is updated regularly.

What is Adbry?

Adbry has active ingredients of tralokinumab. eHealthMe is studying from 1,899 Adbry users. Check the latest studies of Adbry.

What is Eye infection?

Eye infection is found to be associated with 834 drugs and 768 conditions by eHealthMe. Check the latest studies of Eye infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

1,898 people reported to have side effects when taking Adbry.
Among them, 14 people (0.74%) have Eye infection.

Among these 14 people:

How long have people been on Adbry when they have Eye infection? *

What is the gender of people who have Eye infection when taking Adbry? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Eye infection when taking Adbry? *

What are other drugs people take besides Adbry? *

Dupixent: 2 people, 14.29%
Triamcinolone Acetonide: 1 person, 7.14%
Rosuvastatin Calcium: 1 person, 7.14%
Nexium: 1 person, 7.14%
Metoprolol Succinate: 1 person, 7.14%
Lasix: 1 person, 7.14%
Eliquis: 1 person, 7.14%
Dexamethasone: 1 person, 7.14%
Desoximetasone: 1 person, 7.14%
Albuterol: 1 person, 7.14%

What are other side effects people have besides Eye infection? *

Swelling Face: 2 people, 14.29%
Rashes (redness): 2 people, 14.29%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 2 people, 14.29%
Withdrawal Syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance): 1 person, 7.14%
Fungal Infection: 1 person, 7.14%
Cellulitis (infection under the skin): 1 person, 7.14%
Corneal Deposits: 1 person, 7.14%
Drug Ineffective: 1 person, 7.14%
Dry Skin: 1 person, 7.14%
Eye Pruritus (eye itching): 1 person, 7.14%

What are the existing conditions these people have? *

Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 13 people, 92.86%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 7.14%
Asthma: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Adbry and have Eye infection?

- Check whether Eye infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adbry:

Adbry (1,899 reports)

Eye infection treatments and more:

Eye infection (14,222 reports)

Browse all side effects of Adbry:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eye infection:

Eye infection (835 drugs)

Browse all the conditions that are associated with Eye infection:

Eye infection (768 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tralokinumab (the active ingredients of Adbry) and Adbry (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.